ADC Therapeutics SA Files 2023 Annual Report on Form 10-K

Ticker: ADCT · Form: 10-K · Filed: Mar 13, 2024 · CIK: 1771910

Adc Therapeutics SA 10-K Filing Summary
FieldDetail
CompanyAdc Therapeutics SA (ADCT)
Form Type10-K
Filed DateMar 13, 2024
Risk Level
Pages15
Reading Time18 min
Sentimentneutral

Sentiment: neutral

Topics: 10-K, Annual Report, Pharmaceuticals, Financials, ADC Therapeutics

TL;DR

<b>ADC Therapeutics SA has submitted its 2023 annual report (10-K) detailing its financial performance and business operations for the fiscal year ending December 31, 2023.</b>

AI Summary

ADC Therapeutics SA (ADCT) filed a Annual Report (10-K) with the SEC on March 13, 2024. ADC Therapeutics SA filed its 2023 Form 10-K on March 13, 2024. The filing covers the fiscal year ending December 31, 2023. The company's principal executive offices are located at Biopole, Route de la Corniche 3B, Epalinges, Switzerland. The Standard Industrial Classification code for the company is Pharmaceutical Preparations [2834]. The filing includes financial data for the fiscal years 2023, 2022, and 2021.

Why It Matters

For investors and stakeholders tracking ADC Therapeutics SA, this filing contains several important signals. This 10-K filing provides a comprehensive overview of ADC Therapeutics' financial health, operational activities, and strategic direction for the past fiscal year, which is crucial for investors to assess the company's performance and future prospects. The detailed financial statements and risk factors disclosed in the 10-K are essential for investors and stakeholders to understand the company's financial position, potential risks, and compliance with regulatory requirements.

Risk Assessment

Risk Level: — ADC Therapeutics SA shows moderate risk based on this filing. The company operates in the pharmaceutical industry, which is subject to significant regulatory oversight, lengthy drug development cycles, and intense competition, posing inherent risks to its financial performance and market position.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand ADC Therapeutics' financial health and strategic positioning in the competitive pharmaceutical market.

Key Numbers

  • 2023-12-31 — Fiscal Year End (The end date of the reporting period.)
  • 2024-03-13 — Filing Date (The date the 10-K was filed with the SEC.)
  • 2023 — Reporting Period (The fiscal year for which the report is filed.)

Key Players & Entities

  • ADC Therapeutics SA (company) — Filer of the 10-K report.
  • 2023 (date) — Fiscal year covered by the report.
  • 2024-03-13 (date) — Filing date of the report.
  • 2834 (dollar_amount) — Standard Industrial Classification code for Pharmaceutical Preparations.

FAQ

When did ADC Therapeutics SA file this 10-K?

ADC Therapeutics SA filed this Annual Report (10-K) with the SEC on March 13, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by ADC Therapeutics SA (ADCT).

Where can I read the original 10-K filing from ADC Therapeutics SA?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by ADC Therapeutics SA.

What are the key takeaways from ADC Therapeutics SA's 10-K?

ADC Therapeutics SA filed this 10-K on March 13, 2024. Key takeaways: ADC Therapeutics SA filed its 2023 Form 10-K on March 13, 2024.. The filing covers the fiscal year ending December 31, 2023.. The company's principal executive offices are located at Biopole, Route de la Corniche 3B, Epalinges, Switzerland..

Is ADC Therapeutics SA a risky investment based on this filing?

Based on this 10-K, ADC Therapeutics SA presents a moderate-risk profile. The company operates in the pharmaceutical industry, which is subject to significant regulatory oversight, lengthy drug development cycles, and intense competition, posing inherent risks to its financial performance and market position.

What should investors do after reading ADC Therapeutics SA's 10-K?

Investors should review the detailed financial statements and risk factors in the 10-K to understand ADC Therapeutics' financial health and strategic positioning in the competitive pharmaceutical market. The overall sentiment from this filing is neutral.

How does ADC Therapeutics SA compare to its industry peers?

ADC Therapeutics operates in the highly regulated and competitive biotechnology sector, focusing on the development of novel antibody-drug conjugates (ADCs) for the treatment of cancer.

Are there regulatory concerns for ADC Therapeutics SA?

The pharmaceutical sector is heavily regulated by bodies like the FDA and EMA, requiring extensive clinical trials, manufacturing compliance, and post-market surveillance.

Risk Factors

  • Regulatory Risks [high — regulatory]: The pharmaceutical industry is subject to extensive government regulation, which can impact product development, manufacturing, marketing, and pricing.
  • Market Competition [high — market]: The company faces intense competition from other pharmaceutical and biotechnology companies, which can affect market share and profitability.
  • Research and Development Risks [high — operational]: Drug development is a lengthy, expensive, and uncertain process with a high failure rate, posing significant risks to the company's pipeline and future revenue.

Industry Context

ADC Therapeutics operates in the highly regulated and competitive biotechnology sector, focusing on the development of novel antibody-drug conjugates (ADCs) for the treatment of cancer.

Regulatory Implications

The pharmaceutical sector is heavily regulated by bodies like the FDA and EMA, requiring extensive clinical trials, manufacturing compliance, and post-market surveillance.

What Investors Should Do

  1. Analyze the company's financial statements for revenue trends, profitability, and cash flow.
  2. Review the risk factors section for potential challenges and uncertainties affecting the business.
  3. Assess the company's strategic initiatives and pipeline developments mentioned in the report.

Key Dates

  • 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K.
  • 2024-03-13: Filing Date — Date the 10-K was officially submitted to the SEC.

Year-Over-Year Comparison

This filing is the annual 10-K report for the fiscal year 2023, providing updated financial and operational information compared to previous filings.

Filing Stats: 4,419 words · 18 min read · ~15 pages · Grade level 15.5 · Accepted 2024-03-13 12:25:38

Filing Documents

Risk Factors

Item 1A. Risk Factors 34

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 62

Cybersecurity

Item 1C. Cybersecurity 62

Properties

Item 2. Properties 62

Legal Proceedings

Item 3. Legal Proceedings 63

Mine Safety Disclosure

Item 4. Mine Safety Disclosure 63 PART II 63

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 63

Reserved

Item 6. Reserved 66

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 66

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 76

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 77

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 120

Controls and Procedures

Item 9A. Controls and Procedures 120

Other Information

Item 9B. Other Information 120

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 120 PART III 121

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 121

Executive Compensation

Item 11. Executive Compensation 125

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 141

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 143

Principal Accounting Fees and Services

Item 14. Principal Accounting Fees and Services 144 PART IV 144

Exhibits, Financial Statement Schedules

Item 15. Exhibits, Financial Statement Schedules 144

Form 10-K Summary

Item 16. Form 10-K Summary 146 Unless otherwise indicated or the context otherwise requires, all references in this Annual Report to "ADC Therapeutics," "ADCT," the "Company," "we," "our," "ours," "us" or similar terms refer to ADC Therapeutics SA and its consolidated subsidiaries. Trademarks We own various trademark registrations and applications, and unregistered trademarks, including ADC Therapeutics, ADCT, ZYNLONTA and our corporate logo. All other trade names, trademarks and service marks of other companies appearing in this Annual Report are the property of their respective owners. Solely for convenience, the trademarks and trade names in this Annual Report may be referred to without the and symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend to use or display other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Market and Industry Data This Annual Report contains industry, market and competitive position data that are based on general and industry publications, surveys and studies conducted by third parties, some of which may not be publicly available, and our own internal estimates and research. Third-party publications, surveys and studies generally state that they have obtained information from sources believed to be reliable, but do not guarantee the accuracy and completeness of such information. These data involve a number of assumptions and limitations and contain projections and estimates of the future performance of the industries in which we operate that are subject to a high degree of uncertainty. Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Annual Report contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future catalysts, results of operations and financial position, business and commercial strategy, market opportunities, products and product candidates, research pipeline, ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals, research and development costs, projected revenues and expenses and the timing of revenues and expenses, timing and likelihood of success, as well as plans and objectives of management for future operations are forward-looking statements. Many of the forward-looking statements contained in this Annual Report can be identified by the use of forward-looking words such as "anticipate," "believe," "could," "expect," "should," "plan," "intend," "estimate," "will" and "potential," among others. Forward-looking statements are based on our management's beliefs and assumptions and on information available to our management at the time such statements are made. Such statements are subject to known and unknown risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to: the substantial net losses that we have incurred since our inception, our expectation to continue to incur losses for the foreseeable future and our need to raise additional capital to fund our operations and execute our business plan; our indebtedness under the loan agreement and guaranty (the "Loan Agreement") with certain affiliates and/or funds managed by each of Oaktree Capital Management, L.P. and Owl Rock Capital Advisors LLC, as lenders, and Blue Owl Opportunistic Master Fund I, L.P., as administrative agent, and the associated restrictive covenants thereunder; the purchase and

Business

Item 1. Business Overview ADC Therapeutics is a leading, commercial-stage global pioneer in the field of antibody drug conjugates ("ADCs") with a validated and differentiated technology platform with multiple payloads and targets, a robust next-generation research and development toolbox, and specialized end-to-end capabilities. We are advancing our proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. We leverage our scientific and technical expertise and apply a disciplined approach to target selection to expand and advance our pipeline. We have created a diverse clinical and research pipeline that we are advancing with the goal of transforming the cancer treatment paradigm across both hematology and solid tumors. We are also seeking to expand the label for our marketed product, ZYNLONTA (loncastuximab tesirine) into new indications. Our portfolio of ADCs utilizes our highly potent pyrrolobenzodiazepine ("PBD") technology, a differentiated exatecan-based payload with a novel hydrophilic linker and a next generation ADC toolbox. In the hematology space, our flagship product, ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration ("FDA") and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma ("DLBCL") after two or more lines of systemic therapy. We are seeking to continue expanding ZYNLONTA into international markets throughout the world, and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma ("FL") and marginal zone lymphoma ("MZL"), as a single agent and in combination through our LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial as well as through investigator-initiated trials ("IITs") at leading institutions. In addition, we are investigating a CD-22 targeted compound, ADCT-602, in a Phase 1/2 investigator-i

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.